User talk:Sushma jyothula

15th International Conference on Pharmaceutical Formulations & Drug Delivery is scheduled to be held during September 17-18, Philadelphia, USA. This Pharma Formulations 2018 includes a wide range of Keynote presentations, Plenary talks, Symposia, Workshops, Exhibitions, Poster presentations and Career development programs

Conference series LLC Organizes 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Pharma Formulations 2018 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about formulations and drug delivery and its advances. This is your best opportunity to reach the largest assemblage of participants from Pharma research community that is from academia, drug delivery entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.

Pharma Formulations 2018 will discuss various disciplines involved in the drug formulation procedures and drug delivery technologies; it will educate health care researchers about design, operation, organizing, research computing, regulatory aspects and reporting of formulations. This conference conduct presentations, distribute information, meet with current and potential scientists, make a splash with new pharma research developments, and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in formulations and drug delivery are hallmarks of this conference.

Who Should Attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of

CROs and CMOs Pharma Research Sites Pharma/Biotech and Medical Device industries Hospitals, Associations Medical Directors, Principal Investigators, Methodologists, and other Pharmaceutical research professionals along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professor, Research Scholars, scientists who are related to pharmceutical research.

Sessions/Tracks 15th International Conference on Pharmaceutical Formulations & Drug Delivery includes 18 Tracks/ Sessions and 80+ Sub-Tracks which covers all the aspects of Pharmaceutical formulations and drug delivery starting Bioavailability, Additives, Uniformity, Preclinical & Clinical Formulations, Process Development Studies, and Process Scale-Up Studies, Formulation Modification, Manufacture Validation, Formulation Optimization & Finalization, Packaging Compatibility. It also focused on drug discovery, drug designing, development and drug delivery.

Track 1: Pharmaceutical Formulations: Academic and Industy Perspective

Increasingly, medicines research is moving from ‘big pharma’ to small biotech companies and start-ups. To succeed in this new environment, scientific skills are not enough employers and financiers also need to be confident that the people they are working with possess the entrepreneurial skills to grow and sustain a business effectively. Pharmaceutical formulation development enables development of robust and compliant formulations and resolve difficult challenges encountered during preclinical and clinical development.

Related Conferences & Societies International Pharmaceutical Conference and Expo, May 2-4, 2018, Rome Italy, Pharma Market Research Conference, June 12-13, 2018, San Francisco, USA, Outsourced Pharma Conference and Exhibition, May 14-15, 2018, Boston, USA, American Association of Pharmaceutical Scientists (AAPS) The Academy of Pharmaceutical Sciences, Pharmaceutical Society of Australia.

Track 2: Pharmaceutical Excipients Development

Pharmaceutical excipients have a vital role in formulations. Choosing of excipients is an important in Drug Development. Excipients will have the ideal pharmacokinetic properties. Existing regulations and guidelines indicate that new (novel) excipients should be treated as new chemical entities with full toxicological evaluation. Excipients are now known to have defined functional roles in pharmaceutical dosage forms. Excipients can influence both safety and efficacy outcomes of the drugs. Excipients play a vital role in Drug delivery systems. Excipients are  designed  to  be biologically  inactive,  removing  this  barrier  could  provide  a potentially immediate, low-risk solution to the current shortage of new drug formulations.

The global excipient is expected to grow to $8.8 billion in 2018, a compound annual growth rate (CAGR) of 6.9% over the five-year period from 2013 to 2018.

Related Conferences & Societies

APS Current Regulatory Trends and Updates in Parenteral Drug Product Development, March 20-21, 2018, Loughborough, UK, 6th World Health Professions Regulation Conference, May 19-20, 2018, Geneva, Switzerland, American Association of Pharmacognosy, Austrian Pharmaceutical Society, European Pharmaceutical Union (EPU).

Track 3: Drug Designing and Development

Researchers discover new drugs through insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease. Once researchers identify a promising compound for development, they conduct experiments to gather information on how it is absorbed, distributed, metabolized, and excreted, best dosage, Side effects, how it interacts with other drugs and treatments and its effectiveness as compared with similar drugs.

Bringing one new drug to the public typically costs a pharmaceutical or biotechnology company on average more than $1 billion and takes an average of 10 to 15 years. Each drug undergoes a stringent process of discovery, development, approval and finally, public use.

Related Conferences & Societies

Inhalation & Respiratory Drug Delivery USA Congress, 12-13 March 2018, San Diego, USA, 9th Global Drug Delivery Summit, 12-14 March 2018, Berlin, 11th World Meeting on Pharmaceutics, Pharmaceutica Technology Biopharmaceutics, 19-22 March 2018, Granada, Spain, Canadian Society for Pharmaceutical Sciences, Illinois Pharmacists Association.

Track 4: Novel Drug Formulation Procedures

Novel Drug Formulation Procedure is a innovative drug development method which focus to employ the novel methodologies developed by pharmaceutical industry for a specific intentional use in pharmaceutical Research and development.

Novel drug procedure with unique mechanism offers a much needed treatment option to improve the condition. Bioavailability of the API may be exchanged off when attempting to modify entry of the API due to parts, for instance, gastric upkeep or bypassing the absorptive "window" of the duodenum.

Related Conferences & Societies

Controlled Release Delivery, 21st March To 22nd March 2018, London, UK, 15th International Nano medicine and Drug Delivery Summit, September 22-24, 2018, ann arbor, USA, 18th World Congress of Basic and Clinical Pharmacology, July 1-6, 2018, kyoto, japan, National Pharmaceutical Association, University College of Pharmaceutical Sciences.

Track 5: Pharmaceutical Nanotechnology: Challenges and Opportunities

Pharmaceutical nanotechnology is most innovative field in the pharmaceutical industry. Nano technology is dealing with new emerging technologies. Application of nanotechnology in imaging, diagnostics and therapeutics is considered as an important factor. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. Within regulatory boundaries thermodynamics and nanotechnology are considered to be evolving tools to provide new and integrated knowledge for the production of new medicines.

Nanotechnology speaks to a stage for creating progressive changes and enhancements to a wide range of parts of pharmaceutical assembling. Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of disease at a molecular level. Nano technology is having an utmost importance in Gene therapy.

Related Conferences & Societies

3rd International Conference On Drug Delivery, And Tissue Engineering  Nanomedicine, April 10 - 12, 2018, Budapest, Hungary, 3rd World Congress & Exhibition on Antibiotics and Antibiotic Resistance, 31st July- 1st August, 2018, Milan Italy. Ontario Pharmacists' Association, Drug Information Association (DIA), Royal Pharmaceutical Society.

Track 6: Pharmaceutical Formulations: Types and Novelties

Pharmaceutical formulations vary on the route of administration. Eternal formulations prolong the action of duration of drug. Eternal formulation includes tablet, capsule and sustained release dosage forms. Parenteral formulation impacts both the safety and efficacy of drug.

The effect of the dosage form depends on the route of administration. A low medication load may cause homogeneity issues. A high medication load may posture stream issues or require extensive containers if the compound has a low mass thickness.

Related Conferences & Societies

Bioanalytical and Formulation Summit, 9 - 10 October 2018, Dublin, Ireland, Global Pharma Meet and Expo, April 02-04, 2018, Dubai, 2nd International Summit on Pharma and Clinical Trials, June 11-12, 2018, Paris, France, Generic Pharmaceutical Association (GPhA), Medical Device Manufacturers Associations ( MDMA ).

Track 7: Bioavailability and Bioequivalence Studies

Bioavailability and Bioequivalence are designed to FDA evaluation of the safety and effectiveness of a product .BA for a given formulation provides an estimate of the relative fraction of the orally 94 administered doses that is absorbed into the systemic circulation. Bioavailability and Bioequivalence mainly focus on the release of a drug substance from a drug. Several in-vitro and in-vivo methods are used to measure the bioavailability of the drugs. For BA and BE studies a single-dose, fasting study be performed. BA studies provide other useful pharmacokinetic information related to distribution, elimination, the effects of nutrients on absorption of the drug, dose proportionality, linearity in pharmacokinetics of the active moieties and, where appropriate, inactive moieties.

Related Conferences & Societies

3rd Global Bioequivalence Harmonization Initiative GPHI meeting, April 12-13, 2018, Amsterdam, The Netherlands, International Conference on Pharmacognosy and Medicinal Plants, April 16- 17, 2018, Hertfordshire, Netherlands, Applied Pharmaceutical Nanotechnology Society, American Association of Colleges of Pharmacy.

Track 8: Pharmaceutical Analysis Methods

For the administration of drugs various chemical and instrumental methods were developed at regular intervals which are involved in the estimation of drugs. Analytical instrumentation and methods play an important role. Different analytical techniques and electrochemical methods like Chromatographic techniques, HPLC, Gas chromatography. From the stages of drug development to marketing and post marketing, analytical techniques play a great role in understanding the physical and chemical stability of the drug, identification of impurities. Analytical techniques are mainly used to determine the safety and efficacy of the drug.

Related Conferences & Societies

APhA 2018 Annual meeting and Exposition, March 16-19, 2018, Downtown Nashville, USA, 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences, September 02-06, 2018, GlasGow, UK, The Pharmaceutical and Healthcare Sciences Society (PHSS), Pharmaceutical Research and Manufacturers of America (PhRMA), Controlled Release Society.

Track 9: Challenges in Drug Administration

Medication are used to prevent and illness. Depending upon their site of action and safety and efficacy of drug drugs can be administered through a variety like oral, parenteral, Transdermal, Intradermal etc.. While administering a drug we have to consider the possible side effects and dangerous reactions also. The Dosage of the drug has to be carefully determined. In US, it has been estimated that 80 per cent of active ingredients and 40 per cent of the final drug products are imported. Medicine slant and bolster significance have been surveyed by taking a gander at the self-association of no less than two drugs open under various trial conditions, including choice procedure, dynamic extent fortress timetables, and chain stronghold logbooks.

In 2009, over $12 billion were invested in biologics / biotechnology research and development (R&D), representing a 26% share in the total R&D expenditure

Related Conferences & Societies International Pharmaceutical Conference and Expo, May 2-4, 2018, Rome Italy, Pharma Market Research Conference, June 12-13, 2018, San Francisco, USA, Outsourced Pharma Conference and Exhibition, May 14-15, 2018, Boston, USA, American Association of Pharmaceutical Scientists (AAPS), The Academy of Pharmaceutical Sciences, Pharmaceutical Society of Australia.

Track 10: Drug Delivery Technologies

Particle Sciences has a great deal of successful experience in the development of successful delivery systems for many types of APIs and sites of action. Drug delivery technologies enhance drug absorption, efficacy, and patient experience. Enhancing the drug delivery technology of final pharmaceutical formulation can increase its commercial success. Drug delivery systems have been used in delaying drug clearance processes. Drug delivery approaches have their advantages and limitations. Drug delivery approaches include solubilization, permeability enhancement, modified release (MR)

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period.

Related Conferences & Societies

APS Current Regulatory Trends and Updates in Parenteral Drug Product Development, March 20-21, 2018, Loughborough, UK, 6th World Health Professions Regulation Conference, May 19-20, 2018, Geneva, Switzerland, American Association of Pharmacognosy, Austrian Pharmaceutical Society, European Pharmaceutical Union (EPU).

Track 11: Novel Drug Delivery Systems

Drug delivery systems control the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and efficacy of drugs. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms. Novel drug delivery system classified in to different types based on the diffusion types. Drug Delivery Carriers show great promise as drug delivery systems. Drug delivery may be either active or passive process. These are designed to target the site specific region, in order to achieve desired therapeutic effect, thereby reducing the side or toxic effects. NTTD Increases the efficacy of the drug and decrease side effects.

The global market for drug delivery systems is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2021.

Related Conferences & Societies

Inhalation & Respiratory Drug Delivery USA Congress, 12-13 March 2018, San Diego, USA, 9th Global Drug Delivery Summit, 12-14 March 2018, Berlin, 11th World Meeting on Pharmaceutics, Pharmaceutica Technology Biopharmaceutics, 19-22 March 2018, Granada, Spain, Canadian Society for Pharmaceutical Sciences, Illinois Pharmacists Association.

Track 12: Wearable Drug Delivery

These are changing the world of drug delivery and preventing the patients from continuous bulk ambulatory devices. Wearable drug delivery device delivers insulin to the wearer. These are developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives. Large doses 5ml to 50 ml can be comfortably be self-administered by the patient at home by using the Wearable Drug Delivery devices. The life cycle of the product can also be increases. Wearable technology speeds the Formulation and development.

The annual growth rate is expected to reach USD $824 bn by 2025. The size of the market opportunity for LVI devices alone has been estimated at $8.1 billion by 2025, with over 50% of this driven by devices to deliver drugs for cancer and related conditions.

Related Conferences & Societies

Controlled Release Delivery, 21st March To 22nd March 2018, London, UK, 15th International Nano medicine and Drug Delivery Summit, September 22-24, 2018, ann arbor, USA, 18th World Congress of Basic and Clinical Pharmacology, July 1-6, 2018, kyoto, japan, National Pharmaceutical Association, University College of Pharmaceutical Sciences.

Track 13: Transdermal & Intradermal Drug Delivery Systems

Transdermal Drug Delivery system is an integral part of novel drug delivery system. Drugs having long pharmacokinetic half-lives are considered to be Unsuitable for transdermal application. By the increased number of marketing authorization applications together with recent scientific developments for transdermal patches, the need for clear guidance on specific requirements for this dosage form increased.

The emergence of technological innovations in transdermal patches is expected to provide the market with lucrative growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.

Related Conferences & Societies

3rd International Conference On Drug Delivery, And Tissue Engineering  Nanomedicine, April 10 - 12, 2018, Budapest, Hungary, 3rd World Congress & Exhibition on Antibiotics and Antibiotic Resistance, 31st July- 1st August, 2018, Milan Italy. Ontario Pharmacists' Association, Drug Information Association (DIA), Royal Pharmaceutical Society.

Track 14: Drug Delivery approaches for Parenterals

Parenteral Drug Delivery has been developed alternative to the normal route of administration. The success depends on clinical as well as on patient compliance. This route is mainly used for the drugs having poor aqueous solubility and this route improves the patient compliance and decreases the systemic availability. Chitosan is used as micro particles, liposomes, granules, and gels for oral and parenteral drug delivery. Parenteral administration route is the most common for delivery of active drug substances with a narrow therapeutic index. This route of administration may cause less cardiac attacks and respiratory attacks. Parenteral delivery still remains the major mode of administration for protein and peptide therapeutics

Related Conferences & Societies

Bioanalytical and Formulation Summit, 9 - 10 October 2018, Dublin, Ireland, Global Pharma Meet and Expo, April 02-04, 2018, Dubai, 2nd International Summit on Pharma and Clinical Trials, June 11-12, 2018, Paris, France, Generic Pharmaceutical Association (GPhA), Medical Device Manufacturers Associations ( MDMA ).

Track 15: Drug Delivery Devices: Approaches and Manufacturing

A new class of drug delivery device which can inject doses far larger than today’s syringes or auto injectors has developed i.e., Bolus Injectors having the capability to deliver more than 1 ml of a drug subcutaneously in a simple, reliable, and inexpensive manner. In the last 12 years, drugs have been delivered using self-regulated and Nano-technology systems. The manufacturers need to consider clinical guidelines and regulatory requirements governing combination products also differ from both pharmaceuticals and medical devices.

To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.

Related Conferences & Societies

3rd Global Bioequivalence Harmonization Initiative GPHI meeting, April 12-13, 2018, Amsterdam, The Netherlands, International Conference on Pharmacognosy and Medicinal Plants, April 16- 17, 2018, Hertfordshire, Netherlands, Applied Pharmaceutical Nanotechnology Society, American Association of Colleges of Pharmacy.

Track 16: Pharmaceutical Regulatory Affairs

Development of a new pharmaceutical product requires at least 15 years because of changes in the regulatory. Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory authorities act a vital role for approval of generics. Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment.

North America and Europe contribute about 57.0% of global pharmaceutical sales. The global regulatory affairs outsourcing market size was valued at USD 4.53 billion in 2016 and is expected to grow at a CAGR of 11.9% over the forecast period.

Related Conferences & Societies

APhA 2018 Annual meeting and Exposition, March 16-19, 2018, Downtown Nashville, USA, 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences, September 02-06, 2018, GlasGow, UK, The Pharmaceutical and Healthcare Sciences Society (PHSS), Pharmaceutical Research and Manufacturers of America (PhRMA), Controlled Release Society.

Track 17: Pharmaceutical Research and Development

For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes  three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.

Related Conferences & Societies

APS Current Regulatory Trends and Updates in Parenteral Drug Product Development, March 20-21, 2018, Loughborough, UK, 6th World Health Professions Regulation Conference, May 19-20, 2018, Geneva, Switzerland, American Association of Pharmacognosy, Austrian Pharmaceutical Society, European Pharmaceutical Union (EPU).